Pharma Focus Asia

Thermo Fisher Expands Cell Culture Media Site in New York

Introduction:

Thermo Fisherpalns for the expansion of new dry powder media manufacturing facility.The facility is expanded to support the production of raw materials used for the manufacturing of  new vaccines and biologic therapies.

Features:

The new expanision adds 45,000 square feet of Animal Origin Free (AOF) manufacturing space.

The new exapsnion is a part of US$650 million multi year investment project to support worldwide supply of media. Moreover, it advances the existing site capabilities to manufacture materials and technology required for the creation of commercial production of new vaccines and biologics including COVID-19 vaccines.

This expanion will address the urgernt supply of raw materials, by providing production redundancy and shorten product manufacturing lead times for customers.The new facility is expected to double the total bioprocess manufacturing capacity by the end of 2023.

The expansion creates more than 100 new jobs for staff across operations, manufacturing, R&D, operations, HR, engineering, and maintenance.

Specifications:

NameThermo Fisher
TypeExpansion
Year2023
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference